Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
January 29, 2024 09:05 ET
|
Inhibikase Therapeutics
Data demonstrated that Risvodetinib was well tolerated up to 7 days of daily dosing with no serious adverse events in healthy volunteers or worsening of symptoms in participants taking anti-PD...
Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli
January 16, 2024 16:05 ET
|
Inhibikase Therapeutics
BOSTON and ATLANTA, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase...
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
December 19, 2023 08:30 ET
|
Inhibikase Therapeutics
BOSTON and ATLANTA, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor...
Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro
December 04, 2023 08:35 ET
|
Inhibikase Therapeutics
- Pre-NDA Meeting to discuss requirements for a 505(b)(2) NDA submission for IkT-001Pro in up to eight blood and stomach cancer indications - - Bioequivalence to 400 mg and 600 mg imatinib mesylate...
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity
November 14, 2023 16:30 ET
|
Inhibikase Therapeutics
BOSTON and ATLANTA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor...
Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023
November 07, 2023 09:28 ET
|
Inhibikase Therapeutics
This release corrects and replaces the headline in the release that was disseminated on November 7, 2023. The reason for this correction is to fix the title which previously stated, "second quarter"...
Inhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023
November 07, 2023 08:00 ET
|
Inhibikase Therapeutics
BOSTON and ATLANTA, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase...
Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment
October 16, 2023 07:00 ET
|
Inhibikase Therapeutics
BOSTON and ATLANTA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor...
Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy
October 04, 2023 08:30 ET
|
Inhibikase Therapeutics
BOSTON and ATLANTA, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor...
Inhibikase Therapeutics Issues a Letter to Shareholders and Comments on Recent Trading Activity
September 20, 2023 08:30 ET
|
Inhibikase Therapeutics
BOSTON and ATLANTA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase...